Effectiveness and safety of hydrogen inhalation therapy as an additional treatment for hypertension in real-world practice: a retrospective, observational study in China.
Hongxiang Ji, Hualin Sun, Yinghui Zhang, Ziyi Zhao, Xin Gao, Chunhe Wang, Yang Yang, Xiaodong Zhang, Jianyong Gao, Dequan Man, Qian Yang, Ying Yang, Chengbin Yue, Changjiang Chen, Xiaoheng Ding, Tongshang Ni · Frontiers in cardiovascular medicine · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
Hydrogen inhalation was associated with greater reductions in systolic and diastolic blood pressure than control treatment through 24 weeks.
What the Researchers Studied
The study examined to evaluate the real-life effectiveness and safety of hydrogen inhalation (HI) therapy as an additional treatment in Chinese adults with hypertension.
How Molecular Hydrogen Was Used
The source material available to H2HUBB did not provide enough detail to identify the molecular hydrogen administration method.
What the Researchers Found
Both mean SBP and DBP levels significantly decreased in the HI group compared to control group at each follow-up visit with the between group difference of -4.63 mm Hg (95% CI, -6.51 to -2.74) at week 8, -6.69 mm Hg (95% CI, -8.54 to -4.85) at week 16, -7.81 mm Hg (95% CI, -9.57 to -6.04) at week 24 for SBP, and -1.83 mm Hg (95% CI, -3.21 to -0.45) at week 8, -2.57 mm Hg (95% CI, -3.97 to -1.17) at week 16, -2.89 mm Hg (95% CI, -4.24 to -1.54) at week 24 for DBP.
H₂ Mechanisms / Biological Findings
The source material reviewed did not establish a specific molecular hydrogen mechanism for the reported findings.
Authors’ Conclusion
The authors concluded that the HI therapy is related to significant amelioration in BP levels with acceptable safety profile in Chinese hypertensive adults after 24 weeks of treatment, building a clinical ground for further research to evaluate the antihypertensive effect of HI therapy.